These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 34687551)
21. Dapagliflozin for the treatment of type 2 diabetes. Anderson SL; Marrs JC Ann Pharmacother; 2012 Apr; 46(4):590-8. PubMed ID: 22433611 [TBL] [Abstract][Full Text] [Related]
22. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478 [TBL] [Abstract][Full Text] [Related]
23. Dapagliflozin for the treatment of type 2 diabetes mellitus - an update. Nicholson MK; Ghazal Asswad R; Wilding JP Expert Opin Pharmacother; 2021 Dec; 22(17):2303-2310. PubMed ID: 34281456 [TBL] [Abstract][Full Text] [Related]
24. Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes. Nakamura Y; Nagai Y; Terashima Y; Nishine A; Ishii S; Kato H; Ohta A; Tanaka Y Expert Opin Pharmacother; 2015; 16(17):2553-9. PubMed ID: 26479189 [TBL] [Abstract][Full Text] [Related]
25. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition? Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934 [TBL] [Abstract][Full Text] [Related]
26. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Reed JW Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054 [TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen AJ Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697 [TBL] [Abstract][Full Text] [Related]
28. Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene. Olson KC; Dellinger RW; Zhong Q; Sun D; Amin S; Spratt TE; Lazarus P Drug Metab Dispos; 2009 Oct; 37(10):1999-2007. PubMed ID: 19589876 [TBL] [Abstract][Full Text] [Related]
29. Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid. Callegari E; Lin J; Tse S; Goosen TC; Sahasrabudhe V CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):127-136. PubMed ID: 33314761 [TBL] [Abstract][Full Text] [Related]
30. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Kasichayanula S; Chang M; Liu X; Shyu WC; Griffen SC; LaCreta FP; Boulton DW Adv Ther; 2012 Feb; 29(2):163-77. PubMed ID: 22271159 [TBL] [Abstract][Full Text] [Related]
31. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders. Shaikh S; Rizvi SM; Shakil S; Riyaz S; Biswas D; Jahan R Biotechnol Appl Biochem; 2016; 63(1):145-50. PubMed ID: 25402624 [TBL] [Abstract][Full Text] [Related]
32. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes. Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313 [TBL] [Abstract][Full Text] [Related]
35. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853 [TBL] [Abstract][Full Text] [Related]
36. Dapagliflozin: an emerging treatment option in type 2 diabetes. Kipnes M Expert Opin Investig Drugs; 2009 Mar; 18(3):327-34. PubMed ID: 19243283 [TBL] [Abstract][Full Text] [Related]
37. In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats. He X; Li Y; Li Y; Guo C; Fu Y; Xun X; Wang Z; Dong Z Biomed Pharmacother; 2023 Jun; 162():114663. PubMed ID: 37027985 [TBL] [Abstract][Full Text] [Related]
39. Dapagliflozin for the treatment of type 2 diabetes. Brooks AM; Thacker SM Ann Pharmacother; 2009 Jul; 43(7):1286-93. PubMed ID: 19584379 [TBL] [Abstract][Full Text] [Related]
40. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]